الفهرس | Only 14 pages are availabe for public view |
Abstract Background : The emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) signifies clonal evolution associated with disease progression to accelerated/blastic phase and reflects the genetic instability of CML The early identification of (ACAs) in Ph+ metaphases at diagnosis by chromosome banding analysis is of clinical and biological importance. Aim of work: The aim of the current study was to evaluate the frequency of additional chromosomal abnormalities (ACAs) at time of diagnosis and during therapy in CML patients presenting with chronic phase or advanced disease (accelerated or blast phase) and to study the impact of (ACAs) as regards patients response to tyrosine kinase inhibitor (TKI) therapy and overall (OS) and event free survival (EFS) |